Sentences with phrase «canadian pharmaceutical patent»

Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada — European Union Comprehensive Economic and Trade Agreement («CETA»):

Not exact matches

The implications for digital and intellectual property issues are particularly important, with chapters on e-commerce and telecommunications services, an extension of patent protections for pharmaceutical drugs could raise health care costs by millions of dollars, and protections for hundreds of geographical indications may restrict Canadian producers of common cheeses, wines, and meats.

In the last decade, Toronto companies held 61 % of U.S. patents granted to Canadian biotech firms, with the companies Aventis Pasteur, NPS Allelix Pharmaceuticals, Hemosol, Visible Genetics, and Spectral Diagnostics ranking in Canada's top five.

Crist has criticized Canadian «promise» case law for invalidating pharmaceutical patents for lack of utility despite the fact that the medicines at issue were commercially successful.

Currently, Canada is the only country that allows brand name pharmaceutical companies to sue generic pharmaceutical companies multiple times on the same patents, adding to the costs and risks of bringing generic drug competition to the Canadian market.

An American pharmaceutical corporation is suing Canadian taxpayers for $ 500 million because we rejected their patents.

However, most of these aspects are already enshrined in Canadian law, while others, such as patent term extensions for pharmaceuticals, are part of the recent Canada - European Union Comprehensive Economic and Trade Agreement, which is awaiting ratification by the Canadian and European governments.

Update 4:35 p.m.: In a ruling today, Federal Court Justice Russel Zinn held in Apotex Inc. v. Pfizer Ireland Pharmaceuticals that the Federal Court had jurisdiction to consider Apotex's impeachment action and motion for summary judgment and declared Pfizer's patent on Viagra, Canadian Patent No. 2,163,466 inpatent on Viagra, Canadian Patent No. 2,163,466 inPatent No. 2,163,466 invalid.

The changing nature of Canadian patents is stirring debate and conversation — in particular, for pharmaceutical companies.

In particular, Eli Lilly claimed that the development of the «promise doctrine» in Canadian patent law led to the invalidation of patents protecting its drugs atomoxetine (Strattera ®) and olanzapine (Zyprexa ®) by Canadian courts, and that this doctrine was radically new, arbitrary, and discriminatory against pharmaceutical companies.

With the implementation of the CETA, as of September 21, 2017, Canadian law now provides for certificates of supplementary protection that extend the term of certain pharmaceutical patents for up to two years.

In a statement, The Council of Canadians points out the EU language was adopted on resolution of pharmaceutical patent disputes.